Olympus and EndoRobotics Announce Exclusive Global Distribution Agreement for FDA-Approved Endoscopic Surgical Robot 'ROBOPERA'
ROBOPERAā¢: Expanding the Reach of Surgical Robotics Globally
Olympus (7733.T), a global leader in medical technology, has entered into an exclusive global distribution agreement with EndoRobotics, a South Korean medical robotics company, for ROBOPERAā¢, a surgical robotic platform. ROBOPERAā¢ is an innovative surgical robotic platform that attaches to existing diagnostic endoscopes and utilizes a micro-cable-driven system, simultaneously improving the precision and accessibility of procedures. The platform received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in September 2025, demonstrating its independent technological credibility worldwide. Olympus aims to incorporate ROBOPERAā¢ into its core EndoTherapy portfolio, creating comprehensive synergy in the therapeutic endoscopy field.
Addressing Unmet Medical Needs in Endoscopic Submucosal Dissection (ESD)
The primary target area for this partnership is the rapidly growing Endoscopic Submucosal Dissection (ESD) market, particularly in the United States. ESD, a standard treatment for early-stage cancers or polyps in the digestive tract, minimizes the physical burden on patients. However, it requires a high level of skill from the physician due to the difficulty in securing operating space and performing precise manipulations. ROBOPERAā¢ significantly reduces the risk of complications such as perforation or bleeding through its sophisticated bimanual manipulation capabilities and stable visualization system. As a result, it lowers the barriers to complex endoscopic procedures, paving the way for a rapid increase in the number of procedures performed and prescriptions written by specialists in the United States.
Driving Standardization of Robotic Systems in the Global Digestive Endoscopy Market
The global gastrointestinal endoscopy market is a massive market, estimated at approximately $16 billion in 2025/2026 and projected to reach $40 billion, driven by an aging population and increased early diagnosis. Within this market, the ESD equipment market, valued at approximately $390 million to $820 million, is the fastest-growing segment for high-value robotic procedures. With competitors such as EndoQuest Robotics accelerating the development of flexible endoscopic surgical robots, Olympus is aiming to gain a first-mover advantage through its collaboration with EndoRobotics. Hospitals can also achieve cost-effectiveness by choosing ROBOPERAā¢, which is compatible with existing endoscopes, instead of adopting expensive stand-alone robotic systems.
VC Perspective: Financial Strategy and Olympus' Pipeline Diversification
The detailed financial terms of this partnership have not been disclosed, but EndoRobotics, the investee company, successfully completed a Series C funding round of 32.5 billion KRW in December 2025, securing a solid financial foundation. The company's valuation at the time was approximately 150 billion KRW on a post-money basis, and this global partnership will significantly reduce the risks associated with overseas expansion. Olympus is pursuing a two-pronged strategy: developing its next-generation Swan EndoSurgical platform while simultaneously commercializing the FDA-approved ROBOPERAā¢ to generate short-term revenue. This is considered an attractive venture capital (VC) investment structure that demonstrates the potential for early commercialization and proactively secures cash flow for investors.
U.S. and Global Launch Schedules and Future Regulatory Strategies
The two companies plan to launch a training program for local specialists in the United States to disseminate the clinical benefits of ROBOPERAā¢. Subsequently, they will prepare for regional launches in major global markets, including Europe and Asia, in line with the timelines for obtaining regulatory approvals and licenses in each country. In particular, whether or not the product is included in each country's medical insurance coverage and whether it meets the guidelines of local regulatory agencies will be key variables in expanding global sales. In the long term, if additional approvals for new product lines such as TraCloser and RollingStitch are obtained, the value of the partnership between the two companies is expected to increase further.
This partnership represents a strategic move by Olympus, which holds a dominant share in the global gastrointestinal endoscopy market, to secure early access to EndoRobotics' FDA 510(k)-approved platform, ROBOPERAā¢, and solidify its leadership in the therapeutic endoscopy field. In the global ESD market, estimated at approximately $390 million in 2025, flexible robotic technology that supports sophisticated bimanual manipulation is poised to revolutionize the standard of care by significantly reducing the difficulty of conventional single-step resection procedures. EndoRobotics, which successfully raised 32.5 billion KRW in Series C funding in December 2025, will leverage Olympus' distribution infrastructure to minimize global marketing costs and maximize commercialization speed, ensuring financial stability. In the medium to long term, the accumulation of early clinical data and reference cases, particularly in the U.S. market, will be a key driver of value creation for both companies, as they compete with companies such as EndoQuest Robotics in the development of flexible endoscopic robotic pipelines.
Source: FierceBiotech (rss)